COSCIENS Biopharma Inc 6-K/A, filed May 30, 2024
COSCIENS Biopharma Inc. (CSCIF)
About this 6-K/A
COSCIENS Biopharma Inc filed this 6-K/A on May 30, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number: 001-38064
Aeterna Zentaris Inc.
(Translation of registrant’s name into English)
c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Explanatory Note
This Amendment No. 1 to this Report on Form 6-K/A (this “Amendment”), originally furnished to the U.S. Securities and Exchange Commission (the “Commission”) on May 15, 2024 (the “Original Form 6-K”), is being furnished to the Commission by Aeterna Zentaris Inc. (the “Company”) solely to include the conformed signature on the consent of Raymond Chabot Grant Thornton LLP (the “Consent”) attached as Exhibit 23.1 to the Original Form 6-K that was erroneously omitted from the Original Form 6-K. The Consent with the conformed signature is attached as Exhibit 23.1 to this Amendment and replaces the Consent attached as Exhibit 23.1 to the Original Form 6-K in its entirety, and is incorporated by reference herein and in the Original Form 6-K by this reference.
Other than as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information contained in the Original Form 6-K, or reflect any events that have occurred after the Original Form 6-K was originally furnished to the Commission.
DOCUMENTS INDEX
| Exhibit | Description | |
| Exhibit 23.1 | Consent of Raymond Chabot Grant Thornton LLP |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AETERNA ZENTARIS INC. | ||
| Date: May 29, 2024 | By: | /s/ Giuliano La Fratta |
| Giuliano La Fratta | ||
| Chief Financial Officer | ||
Exhibit 23.1
| Raymond Chabot Grant Thornton LLP | ||
| Suite 2000 National Bank Tower |
||
| 600
De La Gauchetière Street West Montréal, Quebec |
||
| H3B 4L8 | ||
| Consent of Independent Registered | ||
| Public Accounting Firm | T 514-878-2691 |
We have issued our report dated April 29, 2024 with respect to the consolidated financial statements of Ceapro Inc. included in the Form 6-K of Aeterna Zentaris Inc. filed on May 14, 2024. We consent to the incorporation by reference of the said report in the Registration Statements of Aeterna Zentaris Inc. on Form F-3 (File No. 333- 254680) and on Forms S-8 (File No. 333-224737, File No. 333-210561 and File No. 333-200834).
/s/ Raymond Chabot Grant Thornton LLP
Montréal, Canada
May 14, 2024
| Member of Grant Thornton International Ltd | rcgt.com |